Literature DB >> 16149077

Sodium valproate inhibits glucose transport and exacerbates Glut1-deficiency in vitro.

Hei Yi Wong1, Tsui Shan Chu, Janice Ching Lai, Kwok Pui Fung, Tai Fai Fok, Tatsuya Fujii, Yuan Yuan Ho.   

Abstract

Anticonvulsant sodium valproate interferes with brain glucose metabolism. The mechanism underlying such metabolic disturbance is unclear. We tested the hypothesis that sodium valproate interferes with cellular glucose transport with a focus on Glut1 since glucose transport across the blood-brain barrier relies on this transporter. Cell types enriched with Glut1 expression including human erythrocytes, human skin fibroblasts, and rat astrocytes were used to study the effects of sodium valproate on glucose transport. Sodium valproate significantly inhibited Glut1 activity in normal and Glut1-deficient erythrocytes by 20%-30%, causing a corresponding reduction of Vmax of glucose transport. Similarly, in primary astrocytes as well as in normal and Glut1-deficient fibroblasts, sodium valproate inhibited glucose transport by 20%-40% (P < 0.05), accompanied by an up to 60% downregulation of GLUT1 mRNA expression (P < 0.05). In conclusion, sodium valproate inhibits glucose transport and exacerbates Glut1 deficiency in vitro. Our findings imply the importance of prudent use of sodium valproate for patients with compromised Glut1 function. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16149077     DOI: 10.1002/jcb.20555

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  11 in total

1.  Paroxysmal ocular movements - an early sign in Glut1 deficiency Syndrome.

Authors:  Sofia Reis; Joana Matias; Raquel Machado; José Paulo Monteiro
Journal:  Metab Brain Dis       Date:  2018-05-05       Impact factor: 3.584

Review 2.  Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.

Authors:  Ann A Verhaegen; Luc F Van Gaal
Journal:  Curr Obes Rep       Date:  2021-01-05

Review 3.  Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.

Authors:  A A Verhaegen; L F Van Gaal
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

Review 4.  Valproic acid and nonalcoholic fatty liver disease: A possible association?

Authors:  Edoardo Farinelli; David Giampaoli; Anja Cenciarini; Ephraim Cercado; Alberto Verrotti
Journal:  World J Hepatol       Date:  2015-05-28

Review 5.  Hemiplegic Migraine in Glut1 Deficiency Syndrome and Paroxysmal Dyskinesia at Ketogenic Diet Induction: Case Report and Literature Review.

Authors:  Janina Gburek-Augustat; Anja Heinze; Rami Abou Jamra; Andreas Merkenschlager
Journal:  Mov Disord Clin Pract       Date:  2020-10-06

6.  Clinical Aspects of Glucose Transporter Type 1 Deficiency: Information From a Global Registry.

Authors:  Jian Hao; Dorothy I Kelly; Jianzhong Su; Juan M Pascual
Journal:  JAMA Neurol       Date:  2017-06-01       Impact factor: 18.302

7.  Glucose metabolism as a target of histone deacetylase inhibitors.

Authors:  Suzanne E Wardell; Olga R Ilkayeva; Heather L Wieman; Daniel E Frigo; Jeffrey C Rathmell; Christopher B Newgard; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2008-12-23

Review 8.  Impact of predictive, preventive and precision medicine strategies in epilepsy.

Authors:  Rima Nabbout; Mathieu Kuchenbuch
Journal:  Nat Rev Neurol       Date:  2020-10-19       Impact factor: 42.937

Review 9.  New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants.

Authors:  Mauro Cataldi; Vincenzo Citro; Chiara Resnati; Federica Manco; Giovanni Tarantino
Journal:  Adv Ther       Date:  2021-03-24       Impact factor: 3.845

10.  Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the [U-C(6)]-d-glucose tracer in mice.

Authors:  Richard D Beger; Deborah K Hansen; Laura K Schnackenberg; Brandie M Cross; Javad J Fatollahi; F Tracy Lagunero; Zoltan Sarnyai; Laszlo G Boros
Journal:  Metabolomics       Date:  2009-03-31       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.